- Home
- HHS vs XGN Comparison
HHS vs XGN Comparison
Compare HHS & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- XGN
- Stock Information
- Founded
- HHS 1923
- XGN 2002
- Country
- HHS United States
- XGN United States
- Employees
- HHS N/A
- XGN N/A
- Industry
- HHS Advertising
- XGN Medical Specialities
- Sector
- HHS Consumer Discretionary
- XGN Health Care
- Exchange
- HHS Nasdaq
- XGN Nasdaq
- Market Cap
- HHS 55.0M
- XGN 49.4M
- IPO Year
- HHS N/A
- XGN 2019
- Fundamental
- Price
- HHS $7.45
- XGN $2.65
- Analyst Decision
- HHS
- XGN Buy
- Analyst Count
- HHS 0
- XGN 1
- Target Price
- HHS N/A
- XGN $7.00
- AVG Volume (30 Days)
- HHS 14.9K
- XGN 24.1K
- Earning Date
- HHS 11-07-2024
- XGN 11-11-2024
- Dividend Yield
- HHS N/A
- XGN N/A
- EPS Growth
- HHS N/A
- XGN N/A
- EPS
- HHS N/A
- XGN N/A
- Revenue
- HHS $187,093,000.00
- XGN $56,660,000.00
- Revenue This Year
- HHS N/A
- XGN $9.98
- Revenue Next Year
- HHS $4.05
- XGN $13.63
- P/E Ratio
- HHS N/A
- XGN N/A
- Revenue Growth
- HHS N/A
- XGN 7.05
- 52 Week Low
- HHS $5.50
- XGN $1.30
- 52 Week High
- HHS $8.87
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- HHS 50.77
- XGN 39.30
- Support Level
- HHS $6.66
- XGN $2.64
- Resistance Level
- HHS $7.47
- XGN $3.03
- Average True Range (ATR)
- HHS 0.27
- XGN 0.17
- MACD
- HHS 0.01
- XGN -0.05
- Stochastic Oscillator
- HHS 77.45
- XGN 1.67
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.